News, prices and data come from third-party providers and may be delayed, incomplete, or inaccurate; they are only as reliable as those providers. AI-generated summaries, briefings and analysis can make mistakes, so please verify anything important independently. Everything here is general information only, not investment, financial, tax, or legal advice, and not a recommendation to buy or sell.
A major study on Novartis's drug pelacarsen, designed to lower lipoprotein(a) (Lp(a)) levels, has shown that while the drug effectively reduced Lp(a) in over 8,000 patients, it did not decrease the risk of heart attacks, strokes, or cardiovascular death.
This outcome, announced by Novartis on Friday evening, September 4, 2026, has been described as a setback in cardiology and has raised questions about the treatment approach for elevated Lp(a).
Following the announcement, Novartis shares fell by as much as 3.3% on September 7, and by 7% on September 5, increasing pressure on the company's new pipeline drugs and leading investors to focus on upcoming RNA therapy trial data.
The failure of pelacarsen also casts doubt on the multibillion-dollar race for similar cholesterol-lowering drugs being developed by Amgen and Eli Lilly.
Asgard's AI interpretation of the coverage, not the outlets' own words. Quotes marked verbatim appear word-for-word in the cited outlet's article.
Open the Perspective Plane or Rabbit Hole for a full analysis of how different outlets frame this story.
AI interpretation by Asgard.news, not the sources' own words. Verify against the originals.
Sources marked “Translated” were AI-translated and may contain errors.
Community discussion largely focuses on the negative financial impact on Novartis, with multiple posts highlighting the drastic fall in stock value and the broader implications for the pharmaceutical race. There's a clear sentiment of disappointment and concern regarding the drug's failure and its effect on the company's market position.
“Las acciones de Novartis caen drásticamente tras el segundo contratiempo clínico en días. # Akerix # IA # Novartis # EnsayoClinico # ContratiempoClinico https:// akerix.com/es/article/novartis -stock-crash?5w=1”
“Cholesterol drug setback casts doubt over multibillion-dollar race Novartis’ failure raises the stakes for Amgen and Eli Lilly in the race to turn lower Lp(a) levels into fewer heart attacks and strokes. https://www. cnbc.com/2026/09/08/novartis-c holesterol-setback-drug-race-eli-lilly-amgen.html # TopNews # News # Novartis # Amgen # Lilly”
“Novartis verliert rund 24 Milliarden Franken an Börsenwert Die Papiere des Pharmariesen Novartis steuern am Dienstag gemessen am vernichteten Börsenwert auf einen historischen Tagesverlust zu. Der zweite gewichtige Forschungsrückschlag innerhalb weniger Tage lässt die Aktien des Börsenschwergewichts zeitweise um mehr als 10 Prozent einbrechen. # Novartis # news https://www. awp.ch/sharedarticles?articlei d=-1973123799”
Unverified opinions from third-party public platforms (e.g. Reddit, Lemmy, Bluesky), shown for context only. Not posted, authored, endorsed, moderated, or verified by Asgard, and they may be inaccurate, offensive, or misleading. Report issues via the in-app feedback option.
